Amycretin
GLP-1 and amylin receptor agonist. Once weekly (injectable); once daily (oral).
Catalog reviewed Sep 30, 2026. Feed checks and price reviews are dated separately below. How we verify. Not medical advice.
What to know about Amycretin
An ingredient can have several brands, formulations, and approved uses. Prices and trial findings belong to the specific product and dose shown.
- Mean weight change in the cited trial
- −24.3% (-24.3% at 36 wks · Phase 1b/2a (subcutaneous) · 60 mg weekly (Phase 1b/2a))
Phase 1b/2a (subcutaneous) · 60 mg weekly (Phase 1b/2a)
- FDA shortage report
- In development
Investigational. Not FDA-approved.
- Route & frequency
- Once weekly (injectable); once daily (oral)
Trial averages are not personal predictions. Weight-loss, A1c, and side-effect figures may come from different trials, doses, or populations; follow each source for its context.
Investigational uses
Amycretin (investigational)
Obesity; type 2 diabetes (investigational)
An investigational single molecule that agonizes both the GLP-1 and amylin receptors, in development as both a once-weekly injection and a once-daily oral tablet.
Dosing, warnings & contraindications
Choose the named product and route. These are submitted label records, which may differ from current approved prescribing information. The product links above lead to current prescribing information. Indexed text omits tables and images; always read the full source label.
No approved label (investigational)
Amycretin is investigational. See its registered studies below. Search DailyMed.
Clinical trials
1 registered trials indexed. Showing up to 12 records: posted results first, then late-phase trials. Registry counts are not a measure of evidence quality.
- A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With ObesityNCT06049329PHASE1Completed36 enrolled
Source: ClinicalTrials.gov API v2 · as of Oct 3, 2026
All trials on ClinicalTrials.gov